Format

Send to

Choose Destination
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):585-592. doi: 10.1080/14737167.2018.1508345. Epub 2018 Aug 24.

Guidance toward the implementation of multicriteria decision analysis framework in developing countries.

Author information

1
a Syreon Research Institute , Budapest , Hungary.
2
b Department of Health Policy and Health Economics , Eötvös Loránd University (ELTE) , Budapest , Hungary.
3
c Department of Health Policy , Hanoi University of Public Health , Hanoi , Vietnam.
4
d Center for Health Economics and Policy Studies (CHEPS), Faculty of Public Health , Universitas Indonesia , Depok , Indonesia.
5
e Asfendiyarov Kazakh National Medical University , Almaty , Kazakhstan.
6
f Department of Health Economics , Hanoi Medical University , Hanoi , Vietnam.
7
g Department of Clinical Pharmacy , University of Colorado , Aurora , CO , USA.
8
h Department of Health Services Organization and Management , National School of Public Health , Athens , Greece.
9
i Department of Pharmacotherapy , University of Utah , Salt Lake City , UT , USA.
10
j Abbott Established Pharmaceutical Division, Abbott , Basel , Switzerland.

Abstract

Multiple Criteria Decision Analysis (MCDA) is increasingly used in health care mainly because it moves decision-making from ad hoc to an evidence-based and comprehensive process. Developing countries with more restricted financial and human research capacities, however, should consider their own methods of MCDA development and implementation. Areas covered: An MCDA framework to improve procurement decisions of off-patent pharmaceuticals was developed for developing countries and adapted to Indonesia, Kazakhstan and Vietnam during three policy workshops. Based on the experience of these workshops and one joint workshop with international experts and decision makers from multiple developing countries, general recommendations were formulated on how to implement MCDA specifically in developing countries. We provide 17 practical MCDA implementation recommendations in four major areas, including (1) MCDA objectives; (2) technical considerations of MCDA tool; (3) development and customization of MCDA tool and (4) policy implementation of MCDA in decision-making. Expert commentary: These practical MCDA recommendations for developing countries contribute to feasible, transparent, stepwise, iterative and standardized decision-making in health care.

KEYWORDS:

Decision Making; Developing Countries; Implementation Guidance; Multiple Criteria Decision Analysis; Off-patent Pharmaceuticals

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center